Readnour Robin Shane, DIR, reported an open-market or private sale at AN2 Therapeutics, Inc. involving 16696.000000 shares for an estimated $100312.91. Reported holdings after the transaction were 565592.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
No officer title
The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.
The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.
Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer…
MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP…
Shares held directly by MGC 2018 LP.
Shares held directly by MGC 2018 QP.
0 other filings
0 recent txs